Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,794 total articles
Madison Square Garden Sports (MSGS) shows constructive price action backed by rising short interest, a tight float and improving technicals. We lay out an entry at $338.16 with a $355 target and a $322 stop, sized for a mid-term trade (45 trading days) that aims to capture near-term upside while respecting seasonality and valuation risks.
AMD just showed up to the AI party in force. Strong Q1 2026 results and bullish commentary on EPYC CPUs plus Instinct GPUs produced a 16%-20% post-earnings lift. This trade outlines a disciplined long idea: enter on consolidation, use a tight stop to limit downside, and target a multi-stage re-rating if execution continues and AI spending holds.
Sysco's announced acquisition of Jetro Restaurant Depot creates a combined company with roughly $100B in revenue, immediate margin accretion, and $250M of targeted synergies. With a market cap near $35.4B, an EV/EBITDA of 12 and free cash flow of $1.82B, the risk/reward favors a long position for patient investors who accept integration risk and hi…
Harley-Davidson is a beaten-down iconic brand trading near $2.8B market cap with meaningful cash flow and an active turnaround plan. We upgrade to a bullish stance and recommend a mid-term long trade: entry $25.61, target $31.25, stop $22.00. The risk/reward is attractive given EV/EBITDA ~3.9, free cash flow of $415M, and technical momentum; execut…
Vornado trades at bargain multiples (P/E ~6.8, P/B ~0.93) but those headline metrics obscure an unfinished operating recovery in Manhattan office fundamentals and meaningful leverage. Recent asset buys and a $500M bond issue extend maturities but don't guarantee stabilized NOI. I recommend a mid-term short: enter at the current price, stop at $33.5…
Berkshire Hathaway under Greg Abel is not a broken investment thesis — it’s a capital allocator with a $397B+ war chest, low leverage and a diversified cash engine. Technicals show near-term weakness, creating a disciplined entry for a long-term trade. This plan targets a recovery to new highs while protecting capital with a conservative stop-loss.
Krystal Biotech (KRYS) looks attractive after a market-interpreted Q1 beat and continued commercial traction for VYJUVEK. Strong cash, robust free cash flow, and multiple near-term clinical readouts in 2026-2027 create a clear catalyst path. This trade idea recommends a long at a defined entry with stop and target aligned to key binary events and v…
Nexxen looks like a small-cap mispriced for steady execution. The trade outlined below is an actionable, defined-risk long aiming to capture a structural re-rating driven by product traction, margin recovery, and potential corporate actions.
New Jersey Resources (NJR) reported another quarter of better-than-expected results and sits near its 52-week high on constructive fundamentals: EPS of $3.24, a P/E near 16.7, market cap ~$5.64B and a 3.34% dividend yield. Regulatory rate filings and continued stable distribution operations underpin our bullish view. We lay out a long trade with en…
Amprius (AMPX) is trading near its 52-week high after a sustained rally driven by production progress, NDAA-related defense access, and strong trading flow. The company is priced like a growth winner — market cap ~$2.93B, P/S ~40 — so the trade is a bet that near-term execution (ramp, orders, yields) keeps accelerating. I outline a mid-term swing l…
Luckin is a scale-first, tech-driven coffee chain with rapid unit growth and recovering customer metrics. Near-term headline noise and a controlling-shareholder deal create debate, but revenue growth and a sub-$10B market cap argue for a long-biased trade with a disciplined stop.
Alkermes ($ALKS) is a cash-flowing CNS company that just picked up a sleep medicine asset (Lumryz) via the Avadel deal. The stock is trading near its 52-week high but still offers asymmetric upside to $42.50 if Lumryz momentum and the core CNS portfolio line up. This trade plan targets a mid-term swing (45 trading days) with a disciplined stop at $…
Cameco (CCJ) is the pure-play uranium supplier best positioned to benefit from an accelerating global buildout of nuclear capacity. With a market cap near $49.9B, a large Western-aligned production base, a near-term string of commercial contracts and partnerships including a meaningful stake in Westinghouse, the stock offers a tradeable asymmetric …
Cal‑Maine (CALM) is the largest U.S. producer of shell eggs and is trading like a cyclical producer at the trough. Recent quarter showed sharply lower sales and earnings as egg prices normalized, but the company's balance sheet, free cash flow and strategic moves (Creighton acquisition, specialty egg mix) argue for a recovery. Valuation is compelli…
Sprouts (SFM) looks like a pragmatic long: trading around $79 with a market cap near $7.4B, the stock sits at ~15x forward earnings with healthy free cash flow and a conservative balance sheet. Weak comps and macro sensitivity leave near-term volatility, but management’s buybacks, raised guidance, and store expansion roadmap create a credible path …
Celestica is proving to be a top-tier contract manufacturer and systems integrator for the emerging wave of rack-scale AI infrastructure. Strong Q1 topline growth, an upgraded full-year guide and an AMD partnership make CLS a targeted way to play AI CapEx. This trade idea lays out an entry at $429.00, a stop at $385.00 and a $520.00 target with a 1…
Tenable (TENB) feels punished by headlines about advanced offensive AI models, but the company’s Tenable One platform, new Hexa AI features, positive cash flow and reasonable revenue multiple argue for a tactical long. Growth is slowing relative to prior years and leverage is nontrivial, so size positions and manage risk — entry $21.02, stop $18.50…
Carrier Global (CARR) has shown improving technical momentum after a multi-month consolidation, but the shares trade at a premium relative to free cash flow and earnings. With a market cap near $53.3B, EV ~$66.95B and a P/E in the low-40s, the reward/risk favors a mid-term short if macro or capex indicators weaken. Entry $66.00, stop $71.00, target…
The iShares MSCI South Korea ETF (EWY) has ripped higher as semiconductor leaders and easing geopolitical and energy pressures reduce inflationary risk for the export-heavy Korean economy. Technicals show bullish momentum but elevated RSI and concentration risk argue for a disciplined entry and a close stop. This is a mid-term trade idea aiming to …
Aflac reported another strong quarter, and while the stock has rerated modestly, fundamentals and capital deployment justify a long entry. The insurer offers a durable dividend track record, reasonable valuation metrics (P/E ~15.8; EV/EBITDA ~11), and upside from higher investment income and AI-driven efficiency gains.
Conrad Industries (CNRD) reported $19.9M in 2025 net income ($3.96/diluted share) while backlog slid to $213.9M from $293.8M a year earlier. The shares are trading at about $23.20, implying a trailing P/E near 5.9. Technicals are soft but not broken; short-volume spikes and a one-day days-to-cover profile create episodic volatility. This trade targ…
Prudential (PRU) delivered a resilient outlook despite Japan-related volatility. At roughly $100, a 5.6% yield, sub-10x earnings and solid ROE make PRU a pragmatic swing trade for income-oriented traders. Entry at $99.00, stop $94.00, target $110.00 over a mid-term 45 trading day horizon.
Noah Holdings (NOAH) trades like a story of geopolitical and regulatory downside priced to perfection. At roughly $10.68, the stock carries a market cap of ~$748M, a P/E near 9.7 and a price-to-book around 0.51. Those numbers argue the market is over-discounting the firm's franchise value and earnings power. This trade idea offers a tactical long w…
Halozyme has quietly converted its enzyme platform into a high-margin royalty engine and is layering in M&A to accelerate growth. With 2026 guidance calling for >$1B in royalty revenue and adjusted EBITDA near $1.1B, the stock at ~$66 offers a tactical swing entry to capture a re-rating tied to continued partner sales and integration of Surf Bio. T…
Magna posted strong Q1 results, is streamlining lower-margin businesses and is returning capital while trading at reasonable multiples relative to cash-flow metrics. We like the risk/reward for a long trade that targets a move back toward the 52-week high as margins expand and adjusted EPS rises.
